NMN/NR (Nicotinamide Mononucleotide/Riboside) Geriatric (65+) Dosing

Why NAD+ Decline Matters More After 65

NAD+ concentrations fall steadily with age. That decline accelerates organ-level dysfunction in tissues already stressed by decades of metabolic wear. A 2019 study measuring whole-blood NAD+ in 93 healthy volunteers found levels in participants aged 61 to 87 were approximately 50% lower than those in the 20-to-40 cohort [1]. This depletion is not merely a biomarker. It tracks with reduced mitochondrial respiration, impaired DNA repair via PARP enzymes, and lower sirtuin activity.

For adults over 65, the clinical significance is direct. Lower NAD+ correlates with sarcopenia progression, insulin resistance, and neurodegeneration in preclinical models [2]. The rationale for NMN or NR supplementation in this age group is straightforward: replenish a coenzyme the body no longer synthesizes efficiently. The question is how much to give, and how to account for the physiological changes that make geriatric pharmacology distinct from dosing in younger adults.

Aging kidneys clear metabolites more slowly. Hepatic enzyme capacity shifts. Polypharmacy introduces competition for the same conjugation pathways NMN and NR depend on. These factors don't prohibit supplementation. They demand a more careful approach to dose selection and monitoring.

NMN Dosing: What the Trials Actually Tested

The most cited NMN trial in an older population is Yoshino et al. (2021), published in Science. That study enrolled 25 postmenopausal women (mean age ~60, BMI ≥25) with prediabetes and administered 250 mg/day of NMN orally for 10 weeks. The primary finding: NMN improved skeletal muscle insulin sensitivity by roughly 25% compared to placebo, measured by hyperinsulinemic-euglycemic clamp [3]. No serious adverse events were reported.

Two things matter for geriatric dosing. First, 250 mg/day was enough to produce a measurable metabolic effect. Second, the study population, while not exclusively 65+, included postmenopausal women with metabolic dysfunction typical of older adults.

A Japanese phase I safety trial (Irie et al., 2020) gave single oral doses of 100, 250, and 500 mg NMN to 10 healthy men aged 40 to 60. All doses were well tolerated, with no clinically significant changes in heart rate, blood pressure, oxygen saturation, or sleep quality over 5 hours of monitoring [4]. Fukamizu et al. (2022) extended this work, testing chronic NMN at doses up to 1 to 250 mg/day for 4 weeks in healthy adults. The highest dose elevated blood NAD+ metabolites without triggering safety signals [5].

None of these trials specifically enrolled a 65+ cohort with reduced renal function or significant polypharmacy. For geriatric patients, the prudent starting dose is 250 mg/day of NMN, taken with a morning meal. Titration to 500 mg/day may be considered after 4 to 6 weeks if tolerated and if renal function remains stable.

NR Dosing: A Larger Evidence Base

Nicotinamide riboside (marketed as Niagen) has more published human data than NMN. The CHROMAVITA trial (Martens et al., 2018) randomized 24 lean, healthy adults aged 55 to 79 to NR 500 mg twice daily (1 to 000 mg/day) or placebo for 6 weeks. NR raised whole-blood NAD+ by approximately 60% and lowered systolic blood pressure by a mean of 4.3 mmHg in the crossover analysis [6]. This blood pressure effect is particularly relevant for geriatric patients, many of whom manage hypertension.

Dollerup et al. (2018) tested NR at 2 to 000 mg/day in obese men for 12 weeks and found no serious adverse events, though also no significant changes in insulin sensitivity in that population [7]. The contrast with the Yoshino NMN trial likely reflects differences in dose-response, study population, and the metabolic context of obesity versus prediabetes.

For adults over 65, NR dosing should start at 300 mg/day. The Elysium Basis formulation (NR + pterostilbene at 250 mg/50 mg) was tested in 120 adults aged 60 to 80 in the NRPT trial (Dellinger et al., 2017), showing sustained NAD+ elevation at 4 and 8 weeks without hepatic or renal safety signals [8]. That lower dose produced measurable NAD+ increases, confirming that older adults do not need aggressive doses to shift the NAD metabolome.

Titration to 500 to 600 mg/day is reasonable after 4 weeks. Doses above 1 to 000 mg/day should be reserved for patients under close metabolic monitoring, given the absence of long-term safety data in frail or multimorbid elders.

Renal Considerations in Geriatric NAD Precursor Use

Kidney function declines with age. The average 75-year-old has an eGFR roughly 25 to 30% lower than a 30-year-old, even without diagnosed CKD [9]. NMN and NR are water-soluble, and their metabolites (nicotinamide, methyl-nicotinamide, N-methyl-2-pyridone-5-carboxamide) are renally cleared.

No formal dose-adjustment guidelines exist for NMN or NR in renal impairment. That gap is a problem. In patients with eGFR <45 mL/min/1.73m², metabolite accumulation is plausible. High-dose nicotinamide (the downstream metabolite of both NMN and NR) has been associated with hepatotoxicity and thrombocytopenia at gram-level doses used in dermatology and oncology trials [10].

Practical recommendations for prescribers:

• eGFR ≥60: Standard geriatric starting dose (NMN 250 mg/day or NR 300 mg/day). No special monitoring beyond routine labs.
• eGFR 30 to 59: Start at the same dose but recheck eGFR and liver function at 4 weeks. Hold dose escalation until results are reviewed.
• eGFR <30: Avoid supplementation until more safety data emerge, or use only under nephrology co-management.

A baseline comprehensive metabolic panel and CBC are reasonable before initiating either supplement in any patient over 65.

Drug Interactions and Polypharmacy Risks

Adults over 65 take a median of 5 prescription medications. NMN and NR are not benign additions to a complex regimen, even though they are classified as supplements. Three interaction categories warrant attention.

Hepatotoxic co-medications. Both NMN and NR are converted to nicotinamide, which at high concentrations competes for hepatic methylation via the SAMe pathway. Patients already taking methotrexate, statins (particularly at high doses), or valproate should have liver enzymes monitored more frequently. The AACE 2023 lipid guidelines note that niacin-class compounds can potentiate statin-related hepatotoxicity, and while NMN/NR are not niacin, the shared downstream metabolite creates a plausible risk [11].

Anticoagulants. Nicotinamide has shown antiplatelet effects in animal models. Patients on warfarin, apixaban, or rivarelbaan should have INR or anti-Xa levels checked 2 to 4 weeks after starting NMN/NR. The clinical significance is uncertain, but the monitoring burden is low.

Antidiabetic agents. The Yoshino trial demonstrated improved insulin sensitivity with NMN [3]. For geriatric patients on metformin, sulfonylureas, or insulin, this effect could theoretically increase hypoglycemia risk. The magnitude is likely small at 250 mg/day, but glucose monitoring should be tightened during the first month of supplementation.

The simplest risk-reduction strategy: share the supplement list with a pharmacist trained in geriatric medication review. Many 65+ patients do not disclose supplement use to their prescribers. That omission creates blind spots.

Homocysteine: A Monitoring Blind Spot

Both NMN and NR funnel through the NAD salvage pathway, generating nicotinamide that is methylated by nicotinamide N-methyltransferase (NNMT). This methylation consumes methyl groups from SAMe. Chronic, high-dose NAD precursor use could deplete the methyl donor pool and raise homocysteine levels [12].

Elevated homocysteine is an independent risk factor for cardiovascular disease and cognitive decline. In geriatric patients, baseline homocysteine is already higher due to age-related declines in folate and B12 absorption. Stacking an NAD precursor on top of marginal B-vitamin status could push homocysteine into a clinically concerning range.

The fix is simple. Check homocysteine at baseline and again at 8 to 12 weeks. If levels rise above 15 µmol/L, ensure adequate B12 (≥1 to 000 µg/day methylcobalamin), folate (≥800 µg/day methylfolate), and B6 (25 to 50 mg/day P5P) supplementation before continuing NAD precursor therapy. The Framingham Offspring Study (N=1,965) established that B-vitamin co-supplementation effectively suppresses homocysteine elevation in older adults [13].

Sublingual vs. Oral: Does Route Matter for Older Adults?

NMN is available in sublingual tablets and powders that bypass first-pass hepatic metabolism. One pharmacokinetic study (Huang, 2022) reported that sublingual NMN delivery produced higher peak blood NAD+ levels at 60 minutes compared to an equivalent oral capsule dose [14]. The clinical significance of this difference is unknown.

For geriatric patients, route selection is partly practical. Sublingual tablets require holding the tablet under the tongue for 60 to 90 seconds. Patients with xerostomia (common with anticholinergic medications, tricyclic antidepressants, or Sjögren syndrome) may not dissolve sublingual formulations adequately. Patients with dysphagia may prefer sublingual over capsules. The choice should be individualized.

NR is available only as oral capsules in studied formulations. No sublingual NR product has been evaluated in published trials.

If a clinician opts for sublingual NMN, the starting dose remains 250 mg/day. Higher bioavailability does not justify a lower starting dose in the absence of validated pharmacokinetic data specific to adults over 65.

Timing, Duration, and When to Stop

Morning dosing is preferred. NAD+ has a circadian rhythm, peaking during waking hours in alignment with CLOCK gene regulation [15]. Taking NMN or NR in the evening could theoretically disrupt sleep architecture, though no trial has demonstrated this directly. Several patient-reported surveys on NR use note insomnia as an occasional complaint with evening dosing.

There is no defined treatment duration. The longest published NR trial ran 12 weeks. The longest NMN trial ran 12 weeks as well. Extrapolating beyond that timeframe is standard practice but not evidence-based. A reasonable framework for geriatric patients:

• Weeks 0 to 4: Starting dose. Check tolerability. Baseline labs including CMP, CBC, homocysteine, and fasting glucose.
• Weeks 4 to 6: Recheck labs. Titrate to mid-range dose if tolerated (NMN 500 mg/day or NR 500 to 600 mg/day).
• Weeks 8 to 12: Recheck homocysteine and liver function. Assess subjective endpoints (energy, cognition, physical function).
• Every 6 months thereafter: Routine monitoring. Reassess whether continued use aligns with the patient's goals and overall medication burden.

Discontinuation does not produce withdrawal. NAD+ levels return to pre-supplementation baseline within 2 to 4 weeks of cessation based on washout data from the Martens crossover trial [6]. There is no rebound effect requiring taper.

Deprescribing Context: Does NAD Precursor Therapy Fit?

Geriatric medicine emphasizes deprescribing: reducing unnecessary medications to lower side-effect burden and improve quality of life. Adding NMN or NR moves in the opposite direction. That tension deserves honest discussion.

The American Geriatrics Society Beers Criteria do not list NMN or NR because they fall outside conventional pharmacopeia. But the principle applies. Any substance added to a geriatric regimen should have a clear therapeutic target, a defined monitoring plan, and a discontinuation trigger.

For NAD precursors, reasonable therapeutic targets include: measurable NAD+ elevation on blood testing, improved HbA1c in prediabetic patients, or subjective improvement in fatigue or physical function validated by a standardized tool like the SF-36 or timed up-and-go test.

If none of these targets show improvement after 12 weeks at an adequate dose, stopping the supplement is appropriate. The goal is not indefinite supplementation. It is time-limited therapeutic trial with predefined success criteria.

The 2023 Endocrine Society scientific statement on aging and metabolism notes that "NAD+ repletion strategies show preclinical promise but require larger, longer human trials before incorporation into clinical practice guidelines" [16]. That framing should guide prescriber conversations with patients: this is an emerging intervention, not a validated standard of care.

NMN Regulatory Status: A Practical Note

In November 2022, the FDA determined that NMN could not be marketed as a dietary supplement because it was being investigated as a new drug (by Metro International Biotech). That decision remains under legal challenge. As of mid-2026, NMN products are still widely sold online and in retail settings, but their regulatory status is ambiguous in the United States [17].

NR (Niagen) retains Generally Recognized as Safe (GRAS) status and is sold as a dietary supplement without restriction. For geriatric patients and their prescribers, NR carries less regulatory uncertainty.

This distinction matters for continuity of supply. A patient started on NMN could face product unavailability if enforcement actions increase. NR is a more stable long-term choice from a supply-chain perspective, independent of any pharmacological comparison.

Geriatric-Specific Monitoring Schedule

Baseline labs before starting NMN or NR in a patient over 65: comprehensive metabolic panel, CBC with differential, fasting glucose, HbA1c, homocysteine, vitamin B12, folate, and INR if on anticoagulation. Recheck CMP, homocysteine, and glucose at week 4 to 6. Recheck full panel at week 12. Every 6 months after that if continuing therapy.